Lower middle market private equity firm Quad-C Management Inc. has sold portfolio company Boulder Scientific Co., an organometallic compounds manufacturer, to Iron Path Capital LP.
Quad-C didn’t disclose the financial terms of the transaction in a Wednesday, Nov. 11, statement.
Iron Path said in its own statement that the acquisition marks the first investment from its second flagship fund, which closed with $450 million in commitments in October.
The Deal reported in January that Quad-C was in discussions with investment advisers regarding its exit options for Boulder Scientific, which was said to generate Ebitda north of $30 million.
Quad-C said that its ownership supported the company’s transition from family ownership and accelerated its growth through significant capital investments in its production facilities to expand capacity and extend capabilities.
The firm also aided in the expansion of its technical and commercial services to serve a broader range of customers and end markets, including semiconductor materials, aerospace and defense.
Iron Path plans to support Boulder Scientific’s next phase of growth through continued investment and expansion into existing and new end markets.
Mead, Colo.-based Boulder Scientific manufactures and markets organometallic compounds used in life sciences, electronics and other high-growth applications. Quad-C invested in the company in July 2019 in a deal valued at up to $250 million, according to SPS by With Intelligence, with Antares Capital LP and Churchill Asset Management LLC providing financing for the deal.
Founded in 2021 by Quad-C veteran Rob Reistetter and executive and investor Scott Mraz, Nashville-based Iron Path Capital makes control investments in lower middle market healthcare and specialty industrial companies. It targets companies that generate between $5 million and $15 million in Ebitda with recurring cash flows.
Charlottesville, Va.-based Quad-C is a middle market firm that specializes in partnering with entrepreneurs and management teams to invest in established companies across sectors such as business services, healthcare and industrials. It’s invested in more than 85 platform companies.
In May 2022, the firm announced the final close of its latest fund, Quad-C Partners X LP, with about $1.7 billion in commitments, compared with $1.1 billion for Fund IX. It reportedly seeks $2 billion for its 11th fund.
Boulder Scientific tapped Piper Sandler Cos. for financial advice. A White & Case LLP team led by Matthew Jason Kautz, Brandon Dubov and Alexia Kavaleff provided counsel, The Deal has learned. CEO Rich Preziotti worked on the deal internally alongside Reistetter, as well as Quad-C senior partner Tom Hickey and vice president Anders Grorud.

